Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04320745 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 168
- Enrollment target
NCT04320745 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 168 participants.
The verdict
NCT04320745, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 168 participants
- Enrollment target
Study Summary
This study will evaluate the effect of a once daily Androderm® dose on Blood Pressure (BP) in adult hypogonadal men as measured by 24-hour ABPM.
Interventions
- DRUG Androderm®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2020-05-19 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04320745
The ClinicalTrials.gov registry entry for NCT04320745 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Androderm® is the first listed.
NCT04320745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04320745 about?
NCT04320745 is a clinical study titled "A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants". This study will evaluate the effect of a once daily Androderm® dose on Blood Pressure (BP) in adult hypogonadal men as measured by 24-hour ABPM.
What is the current status of trial NCT04320745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 168 participants. The study started on 2020-05-19. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT04320745?
The interventions under investigation include: Androderm® (DRUG).
Who is sponsoring clinical trial NCT04320745?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.